ARS制药公司在对其新的鼻鼻喷剂进行积极审查后,获得“Buy”评级和28.80美元的目标价格。 ARS Pharmaceuticals gets a "Buy" rating and $28.80 target price after positive reviews for its new nasal spray.

ARS制药公司得到了威廉·布莱尔的“优异”评分和奥本海默公司40美元的价格目标,以及导致协商一致的“Buy”评分和28.80美元目标价格的其他积极评分。 ARS Pharmaceuticals received an "outperform" rating from William Blair and a $40 price target from Oppenheimer, among other positive ratings leading to a consensus "Buy" rating and a $28.80 target price. 该公司正在研制一种用于治疗严重过敏反应的鼻涕喷雾,市场上限为10.9亿美元。 The company is developing a nasal spray for treating severe allergic reactions and has a market cap of $1.09 billion. 机构投资者拥有68.16%的股权。 Institutional investors own 68.16% of the stock.